Group 1 - Zhipu AI (02513) saw a price increase of over 10% during trading, currently up 7.4%, following the announcement of its first closed-source model GLM-5-Turbo and a 20% price hike for its new model API [1] - Capital Airport (00694) dropped over 4% after JPMorgan downgraded its investment rating from "Neutral" to "Underweight" and cut the target price by 40% to HKD 1.8, citing structural challenges and potential selling pressure from being removed from the Hong Kong Stock Connect list [1] - Cloudwalk Technology (02670) rose over 7% after signing a strategic cooperation agreement with SF Express to define new standards for building delivery [1] Group 2 - Yiming Anke-B (01541) increased by over 8% after receiving approval for its II phase clinical study of IMM0306 for treating Primary Membranous Nephropathy [2] - WanGuo Data-SW (09698) surged over 12.6% after reporting a net revenue of RMB 11.4323 billion (USD 1.6348 billion) for the year, a 10.8% year-on-year increase, with adjusted EBITDA also up by 10.8% [2] - Automotive stocks collectively fell, with Li Auto-W (02015) down 6.24%, Xpeng Motors-W (09868) down 4.35%, and Great Wall Motors (02333) down 2.64%, amid warnings from multiple CEOs about rising chip costs [2] Group 3 - Smoore International (06969) opened slightly higher but fell 15.21% after reporting a revenue of approximately RMB 14.256 billion for 2025, a 20.8% increase, but a net profit decline of 18.5% [3] - China Cosco Shipping Energy Transportation (01138) rose 5.39% as reports indicated significant impacts on the tanker and energy markets due to ongoing Middle East conflicts [3] Group 4 - China Oriental Education (00667) increased by 6.57% after reporting a revenue of RMB 4.616 billion for 2025, a 12.1% year-on-year increase, with net profit up 47.5% [4] - Changfeng Pharmaceutical (02652) surged over 21%, currently up 9.99%, after announcing the acceptance of its IND application for a new inhalation powder for treating pulmonary arterial hypertension [4] Group 5 - Swarmer (SWMR.US) debuted on the US stock market with a staggering opening price increase of 315.4%, currently up 520%, focusing on AI-driven drone swarm control systems [5] - 36Kr (KRKR.US) rose 37.39% after reporting a total revenue of RMB 227 million for 2025, with a gross margin increase to 58% and a net profit of approximately RMB 11.42 million [5] - Space-related stocks saw active trading, with Rocket Lab (RKLB.US) up 10.21% and Planet Labs PBC (PL.US) up 10.08% [5] Group 6 - Solaris Energy Infrastructure (SEI.US) rose 10.88% after announcing agreements worth USD 620 million to add approximately 900 MW of gas turbine capacity between 2026 and 2029 [7] - Uber (UBER.US) increased by 4.19% following a partnership with NVIDIA to deploy autonomous taxi fleets in major US cities by 2027 [8] - Aiko Solar (CSIQ.US) rose 1.94% after announcing a supply agreement for a 500 MW energy storage project [8] - Atour (ATAT.US) saw a price increase of 5.98% after reporting a net revenue of approximately RMB 2.788 billion for Q4 2025, a 33.8% year-on-year increase [8]

Airline and Travel Companies - Shares of airlines and travel companies rebounded, with Delta rising more than 6%, Norwegian Cruise Line Holdings climbing over 2%, and Expedia Group jumping more than 4% [1][10][11] - American Airlines Group gained 3.5% after raising its revenue guidance for the current quarter, while United Airlines rose 3.2% [11] Oil Prices and Economic Impact - Concerns over prolonged supply disruptions due to the closure of the Strait of Hormuz have kept crude prices near $100 a barrel [2][11] - The Federal Reserve is expected to keep borrowing costs unchanged, with rate futures suggesting a potential 25-basis-point cut toward the end of the year, down from around two before the conflict [4][11] Market Performance - The S&P 500 climbed 0.25% to end at 6,716.09 points, with eight of the eleven sector indexes rising, led by energy, which was up 1.02% [7][11] - The S&P 500 financials sector index rebounded 0.5%, with asset managers Blackstone, Apollo Global, and KKR seeing gains of 4.6%, 5.3%, and 3.3% respectively [6][11] Trading Volume and Stock Movements - Trading volume on U.S. exchanges was light, with 16.9 billion shares traded compared to an average of 19.8 billion shares over the previous 20 sessions [8][11] - Energy companies Occidental and ConocoPhillips rose about 1% each, tracking higher crude prices [8][11] - Eli Lilly fell nearly 6% after being downgraded by HSBC from "hold" to "reduce" [9][11]

Core Viewpoint - The weight loss drug market is emerging as a significant growth opportunity in the pharmaceutical industry, comparable to the technology sector, with Eli Lilly and Viking Therapeutics as key players [1][2]. Eli Lilly - Eli Lilly leads the weight loss drug market with a 60% share, driven by its products Mounjaro and Zepbound, which have shown triple-digit revenue growth [5][13]. - The company entered the GLP-1 drug market after Novo Nordisk and has focused on increasing manufacturing capacity to meet demand [4][5]. - Lilly's oral weight loss drug is currently under regulatory review, potentially expanding its market presence [6]. Viking Therapeutics - Viking Therapeutics is advancing its candidate VK2735 into phase 3 trials, with promising results suggesting it could compete effectively with Lilly and Novo's offerings [8][9]. - The company has another candidate targeting amylin and calcitonin receptors, which are important for metabolism [10]. - Demand for weight loss drugs is high, providing Viking with an opportunity to capture market share if its trials are successful [10]. Investment Considerations - Both Eli Lilly and Viking Therapeutics are viewed as strong investment opportunities in the weight loss drug market, with Lilly currently generating significant revenue and Viking showing potential for future growth [13][15]. - Lilly's stock has seen a decline of about 8% this year, trading at 28 times forward earnings estimates, while Viking's stock has increased by approximately 2% this year [13][14]. - The upcoming regulatory decision on Lilly's oral weight loss drug could serve as a catalyst for its stock price [15].

If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound. ...

Analyst Rajesh Kumar downgraded the U.S. drugmaker from Hold to Reduce, while cutting the price forecast from $1070 to $850.According to Bloomberg, the downgrade (the stock’s lowest on Wall Street) comes after a bit of back and forth.HSBC downgraded Eli Lilly’s stock to a sell-equivalent last April, citing excessive optimism and unattractive risk-reward. Four months later, they upgraded it to hold, noting potential upside if the obesity market maintains price discipline. However, they have now reassessed, s ...

Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12. ...

Eli Lilly ( NYSE:LLY ) shares have pulled back sharply, falling 9% over the past month, and 13% year-to- date. ...

Group 1: Netflix - Netflix has been a core holding and recently saw a price dip, which presents a buying opportunity around the $75 range [2][3] - The company is expected to walk away from a merger deal with Warner Brothers, which is viewed as a positive move that will enhance its competitive position in Hollywood [4] - The stock is anticipated to recover to around $125 as Netflix continues to dominate the market [4] Group 2: Eli Lilly - Eli Lilly is highly regarded for its GLP-1 drugs, with an upcoming approval for a new pill that is expected to be more effective than competitors [5][6] - The company is positioned to dominate the weight loss drug market, especially with the introduction of GLP-3 next year [7][8] - Eli Lilly is seen as having superior management and products compared to its main competitor, Novo Nordisk [8] Group 3: Micron and Nvidia - Micron shares have increased over 40% in 2026, but there is a belief that the stock is still undervalued due to market doubts about AI growth [9][10] - Micron's earnings are projected to rise significantly, with estimates suggesting earnings could reach over $30 per share, indicating a strong upside potential [10][11] - Nvidia is also viewed as undervalued, trading at a low multiple compared to its historical average, presenting a significant investment opportunity [12][13] Group 4: Tesla - Tesla is currently facing challenges, with a noted lack of focus on its EV business and a shift towards battery storage as its standout segment [15][16] - The company's future reliance on autonomous vehicle technology is questioned, with concerns about its economic viability [17][18] - The stock is perceived to be overvalued, with a suggested fair value around $200, indicating a tough investment outlook [18]

Core Viewpoint - Eli Lilly's stock has faced pressure following a downgrade by HSBC, raising questions about the sustainability of its strong performance in the obesity drug market and whether investors should reassess valuations [1][3]. Stock Performance - The stock declined by 4.2% after the downgrade, although it remains one of the best-performing large-cap healthcare stocks over the past year, with a 14% increase in shares over the last 12 months, significantly outperforming Novo Nordisk, which has seen a decline of over 54% in the same period [2]. Valuation Concerns - HSBC analyst Rajesh Kumar downgraded Eli Lilly from "Hold" to "Reduce" and lowered the price target from $1,070 to $850, citing concerns that the stock may be overvalued relative to its fundamentals [3]. - The analyst noted that the stock is currently "priced to perfection," indicating that much of the optimism regarding Lilly's growth prospects is already reflected in its stock price [4]. Obesity Drug Market Outlook - HSBC revised its outlook for the total addressable market (TAM) for obesity drugs, projecting it to be between $80 billion and $120 billion by 2032, which is significantly lower than the consensus expectation of exceeding $150 billion [5]. - The downgrade reflects concerns about increasing pricing pressures and competition, particularly from Novo Nordisk, which produces Wegovy [6]. Competitive Dynamics - Analysts have warned that rising working capital intensity, pricing pressures, and rebate dynamics at both Eli Lilly and Novo Nordisk suggest that pricing dynamics may worsen [7]. - The divergence in market outlook between Lilly and Novo Nordisk has raised investor concerns, with Lilly's success in the cash-pay channel attributed more to pricing than product differentiation [8]. Pipeline Risks - While Eli Lilly is expanding its obesity drug portfolio, there are potential risks associated with upcoming products, such as the orforglipron pill, with expectations that compliance and persistence may disappoint [9]. - Current market estimates for 2026 revenue from the drug range from $1.1 billion to $1.3 billion, which are viewed as optimistic, especially given Lilly's $1.5 billion pre-launch inventory [10]. Analyst Sentiment - Despite HSBC's cautious stance, healthcare remains an attractive sector overall, described as relatively defensive amid macroeconomic uncertainty [11]. - The consensus among analysts remains positive for Eli Lilly, with 16 out of 19 analysts giving a buy rating, 2 a hold rating, and 1 a sell rating, indicating that the recent pullback may represent a buying opportunity [12].

Core Viewpoint - Eli Lilly's stock has experienced a decline following a downgrade by HSBC, which cited an "inflated market" for obesity drugs and deemed the stock appropriately priced [1] Group 1: Stock Performance - Eli Lilly's stock is currently trading at $967.06, down 2.2% after the downgrade [1] - The stock has a year-to-date deficit of 9.8%, but has gained over 17% in the last 12 months [3] - The 12-month consensus target price for Eli Lilly is $1,201.43, representing a 21.5% premium to current levels [2] Group 2: Analyst Ratings - A majority of analysts remain bullish on Eli Lilly, with 26 out of 30 firms rating it "buy" or better [2] - The recent downgrade by HSBC is notable given the overall positive sentiment from other analysts [1][2] Group 3: Options Market Sentiment - Options traders are leaning bearish, as indicated by a 10-day put/call volume ratio of 1.16, which is higher than 98% of annual readings [4] - The Schaeffer's put/call open interest ratio (SOIR) of 1.60 also ranks higher than all other readings from the past year, suggesting bearish sentiment [4] Group 4: Volatility Expectations - Options for Eli Lilly are currently considered affordable, with a Schaeffer's Volatility Index (SVI) of 37%, which ranks higher than 25% of all other readings from the past year [5] - This indicates that near-term option traders are pricing in relatively low volatility expectations [5]